A study of embryonic stem cell-related proteins in human astrocytomas: Identification of Nanog as a predictor of survival

International Journal of Cancer

Volumn 134, Issue 5, 2014, Pages 1123-1131

  Elsir, Tamador ^a,b   Edqvist, Per Henrik ^c,d   Carlson, Joseph ^b   Ribom, Dan ^a   Bergqvist, Michael ^d   Ekman, Simon ^d   Popova, Svetlana N ^a,c   Alafuzoff, Irina ^a,c   Ponten, Fredrik ^c,d   Nistér, Monica ^b   Smits, Anja ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

astrocytoma; embryonic stem cells (ESC); glioma; Nanog; survival

Indexed keywords

KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; EMBRYONIC STEM CELL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; UPREGULATION;

ASTROCYTOMA; EMBRYONIC STEM CELLS (ESC); GLIOMA; NANOG; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; EMBRYONIC STEM CELLS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; TISSUE ARRAY ANALYSIS;

EID: 84890569802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28441     Document Type: Article

References (46)

1. Louis DN, Ohgaki H, Wiestler OD, et al,. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Soffietti R, Baumert BG, Bello L, et al,. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010; 17: 1124-33.
3. Ohgaki H, Kleihues P,. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-89.
4. Stupp R, Mason WP, van den Bent MJ, et al,. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med 2005; 352: 987-96.
5. Tabatabai G, Stupp R, van den Bent MJ, et al,. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 2010; 120: 585-92.
6. Singh SK, Clarke ID, Terasaki M, et al,. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
7. Singh SK, Hawkins C, Clarke ID, et al,. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
8. Molofsky AV, Pardal R, Morrison SJ,. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 2004; 16: 700-7.
9. Ben-Porath I, Thomson MW, Carey VJ, et al,. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genet 2008; 40: 499-507.
10. Avilion AA, Nicolis SK, Pevny LH, et al,. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17: 126-40.
11. Chambers I, Colby D, Robertson M, et al,. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-55.
12. Mitsui K, Tokuzawa Y, Itoh H, et al,. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-42.
13. Nichols J, Zevnik B, Anastassiadis K, et al,. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-91.
14. Varlakhanova NV, Cotterman RF, deVries WN, et al,. myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation 2010; 80: 9-19.
15. Smith KN, Singh AM, Dalton S,. Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell 2010; 7: 343-54.
16. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
17. Yu J, Vodyanik MA, Smuga-Otto K, et al,. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
18. Wang Y, Mah N, Prigione A, et al,. A transcriptional roadmap to the induction of pluripotency in somatic cells. Stem Cell Rev 2010; 6: 282-96.
19. Liu K, Lin B, Zhao M, et al,. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal 2013; 25: 1264-71.
20. Cao L, Li C, Shen S, et al,. OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer 2013; 13: 82.
21. Sun C, Sun L, Jiang K, et al,. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol 2013; 45: 1099-108.
22. Leng Z, Tao K, Xia Q, et al,. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PloS One 2013; 8: e56082.
23. Dang CV,. MYC on the path to cancer. Cell 2012; 149: 22-35.
24. Sholl LM, Barletta JA, Yeap BY, et al,. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010; 34: 1193-8.
25. Lin T, Ding YQ, Li JM,. Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol 2012; 29: 878-85.
26. Pandya AY, Talley LI, Frost AR, et al,. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 2004; 10: 2709-19.
27. Ryan SL, Schwalbe EC, Cole M, et al,. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 2012; 123: 501-13.
28. Gangemi RM, Griffero F, Marubbi D, et al,. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-8.
29. Ikushima H, Todo T, Ino Y, et al,. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 2011; 286: 41434-41.
30. Wang J, Wang H, Li Z, et al,. c-Myc is required for maintenance of glioma cancer stem cells. PloS One 2008; 3: e3769.
31. Zbinden M, Duquet A, Lorente-Trigos A, et al,. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010; 29: 2659-74.
32. Holmberg J, He X, Peredo I, et al,. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PloS One 2011; 6: e18454.
33. Guo Y, Liu S, Wang P, et al,. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 2011; 59: 763-75.
34. Niu CS, Li DX, Liu YH, et al,. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep 2011; 26: 593-601.
35. Elsir T, Qu M, Berntsson SG, et al,. PROX1 is a predictor of survival for gliomas WHO grade II. Br J Cancer 2011; 104: 1747-54.
36. Uhlen M, Oksvold P, Fagerberg L, et al,. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-50.
37. Kampf C, Olsson I, Ryberg U, et al,. Production of tissue microarrays, #immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 2012; 63: 3620.
38. Paavilainen L, Wernerus H, Nilsson P, et al,. Evaluation of monospecific antibodies: a comparison study with commercial analogs using immunohistochemistry on tissue microarrays. Appl Immunohistochem Mol Morphol 2008; 16: 493-502.
39. Capper D, Zentgraf H, Balss J, et al,. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118: 599-601.
40. Cascon A, Robledo M,. MAX and MYC: a heritable breakup. Cancer Res 2012; 72: 3119-24.
41. Beier D, Hau P, Proescholdt M, et al,. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
42. Joo KM, Kim SY, Jin X, et al,. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
43. Chen J, McKay RM, Parada LF,. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012; 149: 36-47.
44. Daley GQ,. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol 2008; 73: 171-4.
45. Villalva C, Cortes U, Wager M, et al,. O6-Methylguanine-Methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci 2012; 13: 6983-94.
46. Johannessen TC, Bjerkvig R,. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 2012; 12: 635-42.